Acadia Pharmaceuticals (ACAD) EBT (2010 - 2026)

Acadia Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, EBT fell 85.61% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $115.1 million (down 56.55% YoY), while the FY2025 annual figure was $138.9 million, down 46.18% from the prior year.
• EBT was $4.0 million for Q1 2026 at Acadia Pharmaceuticals, down from $26.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of $161.1 million in Q4 2024 to a low of -$112.6 million in Q1 2022.
• Historically, EBT has averaged $8.0 million across 5 years, with a median of $21.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: EBT tumbled 97.35% in 2023, then soared 486.47% in 2024.
• A 5-year view of EBT shows it stood at -$40.8 million in 2022, then jumped by 197.11% to $39.7 million in 2023, then jumped by 306.1% to $161.1 million in 2024, then tumbled by 83.67% to $26.3 million in 2025, then plunged by 84.79% to $4.0 million in 2026.
• The last three EBT figures came in at $4.0 million (Q1 2026), $26.3 million (Q4 2025), and $44.6 million (Q3 2025), per Business Quant data.